Vanguard Group Inc. Sells 15,305 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Vanguard Group Inc. trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 0.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,363,748 shares of the specialty pharmaceutical company's stock after selling 15,305 shares during the period. Vanguard Group Inc. owned about 10.10% of Jazz Pharmaceuticals worth $782,741,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JAZZ. Cape Investment Advisory Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company's stock valued at $36,000 after buying an additional 292 shares in the last quarter. Covestor Ltd boosted its stake in Jazz Pharmaceuticals by 676.5% in the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company's stock worth $51,000 after purchasing an additional 345 shares in the last quarter. Headinvest LLC acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter worth approximately $56,000. Assetmark Inc. raised its position in Jazz Pharmaceuticals by 37.1% during the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company's stock worth $54,000 after buying an additional 119 shares during the last quarter. Finally, V Square Quantitative Management LLC raised its position in Jazz Pharmaceuticals by 63.9% during the 4th quarter. V Square Quantitative Management LLC now owns 680 shares of the specialty pharmaceutical company's stock worth $84,000 after buying an additional 265 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

JAZZ has been the subject of a number of recent research reports. Royal Bank of Canada reissued an "outperform" rating and set a $195.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Stifel Nicolaus lifted their target price on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a "buy" rating in a report on Friday, March 15th. JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, March 22nd. Truist Financial reaffirmed a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Finally, Piper Sandler lifted their price target on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an "overweight" rating in a research note on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $190.00.

Insider Activity

In other news, EVP Neena M. Patil sold 5,000 shares of the business's stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now owns 36,629 shares of the company's stock, valued at approximately $4,016,369.85. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 4.40% of the company's stock.

Jazz Pharmaceuticals Price Performance

JAZZ traded up $0.61 on Friday, hitting $107.97. 1,600,867 shares of the company's stock were exchanged, compared to its average volume of 930,305. Jazz Pharmaceuticals plc has a fifty-two week low of $103.01 and a fifty-two week high of $146.70. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. The firm has a 50-day moving average price of $109.08 and a 200-day moving average price of $117.16. The stock has a market cap of $6.81 billion, a price-to-earnings ratio of 22.26, a P/E/G ratio of 1.65 and a beta of 0.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). The firm had revenue of $901.98 million for the quarter, compared to analyst estimates of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. As a group, equities analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.